Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07242300
PHASE3

Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection in the Treatment of Adult Upper Limb Spasticity .

Sponsor: JHM BioPharma (Tonghua) Co. , Ltd.

View on ClinicalTrials.gov

Summary

This is a phase III clinical study to evaluate the efficacy and safety of recombinant botulinum toxin type A(Eveotox)in adult patients with upper limb spasticity. The purpose of this study was to observe efficacy and safety of Eveotox compared with placebo in adult patients with upper limb spasticity.

Official title: A Phase III Clinical Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) in Adult Patients With Upper Limb Spasticity

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

207

Start Date

2026-01

Completion Date

2028-01

Last Updated

2025-11-21

Healthy Volunteers

No

Interventions

DRUG

Recombinant Botulinum Toxin Type A for injection

Recombinant Botulinum Toxin Type A for injection

DRUG

Placebo

Placebo will be administered in double-blind fashion during treatment cycle 1 only

Locations (2)

Huashan Hospital Fudan University

Shanghai, Shanghai Municipality, China

Yangzhi Affiliated Rehabilitation Hospital of Tongji University

Shanghai, Shanghai Municipality, China